2 UNIVERSITY PLAZA, HACKENSACK, NJ
Market cap: $234.8M (2/10/2026)
Price: $2.92
Investor Presentation
Receive Positive CHMP Opinion for an Additional Dosing Regimen of Every Four Weeks for Elfabrio® (pegunigalsidase alfa) in the EU
Letter to Stockholders
Reports Third Quarter 2025 Financial and Business Results
Seek Re-examination from the EMA for the Negative Opinion for Elfabrio (pegunigalsidase alfa) Alternative Dosing Regimen of Every Four Weeks in the EU
News, Underwriting Agreement, Legal Opinion
Reports Second Quarter 2025 Financial and Business Results
Appoints Gilad Mamlok as its New Senior Vice President and Chief Financial Officer
Q3
Q2
Q1
FY 2024
FY 2023
Effectiveness Notice
Prospectus filed pursuant to Rule 424(b)(5)
Amended Registration Statement for Securities Offered under a Shelf Registration
Registration Statement for Securities Offered under a Shelf Registration
Registration Statement for Securities to be Offered to Employees
Prospectus filed pursuant to Rule 424(b)(3)
Definitive Proxy Statement
Additional Proxy Materials
PRE 14A
Statement of Changes in Beneficial Ownership
Submission Upload
Correspondence
Confidential Treatment Order